News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Industry News Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt November 17, 2020
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ESC 2020 COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020 Michael O'Riordan September 04, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News VA Efforts to Cut HF Readmissions are Working, With No Uptick in Deaths L.A. McKeown June 18, 2020
News Daily News Latest Kawasaki Series Offers Clues to COVID-19 in Kids as Debate Persists Shelley Wood May 14, 2020
News Conference News HRS 2020 Subcutaneous ICD Holds Up Well Against Transvenous Devices Todd Neale May 13, 2020
News Opinion Editor's Corner A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out Shelley Wood March 16, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Industry News New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation February 25, 2020
News Daily News Trials of New Cancer Drugs Failing to Address Potential CV Risks Todd Neale February 10, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2020 Shelley Wood January 31, 2020
News Daily News TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State Michael O'Riordan January 22, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020